2019
Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)
Wang X, Wang R, Zhang C, Zeidan A, Podoltsev N, Huntington S, Gore S, Davidoff A, Ma X. Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US). Blood 2019, 134: 4748. DOI: 10.1182/blood-2019-128821.Peer-Reviewed Original ResearchPopulation-based studyLR-MDSMedian overall survivalOverall survivalClinical effectivenessHypomethylating agentCelgene CorporationMedian durationRed blood cellsMedian timeRing sideroblastsBoehringer IngelheimAdvisory CommitteeLarge population-based studyDaiichi SankyoOlder adultsAbnormal erythroid precursorsTransfusion independence rateEnd Results-MedicareHigh-risk MDSErythropoiesis-stimulating agentsKaplan-Meier statisticsComparative clinical effectivenessEnd of studyPart D coverage
2014
Tumor lysis syndrome and acute anemia in an African-American man with chronic lymphocytic leukemia
Zhang B, Lee AI, Podoltsev N. Tumor lysis syndrome and acute anemia in an African-American man with chronic lymphocytic leukemia. Oxford Medical Case Reports 2014, 2014: 138-140. PMID: 25988058, PMCID: PMC4369993, DOI: 10.1093/omcr/omu053.Peer-Reviewed Original ResearchTumor lysis syndromeAcute hemolytic episodesLysis syndromeHemolytic episodesHigh riskPeripheral blood smear findingsG6PD deficiencyTime of presentationBlood smear findingsChronic lymphocytic leukemiaG6PD-deficient patientsAfrican American menRed blood cellsTransfusion supportSerious complicationsClinical parametersSmear findingsAcute anemiaHematologic emergencyLymphocytic leukemiaTumor cellsBlood streamPatientsBlood cellsOxidative stress